Skip to main content

Peer Review reports

From: Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3

Original Submission
19 Sep 2013 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
21 Nov 2013 Reviewed Reviewer Report - Chris Scarlett
1 Dec 2013 Reviewed Reviewer Report - Adnan Nagrial
2 Jan 2014 Author responded Author comments - Dirk Spitzer
Resubmission - Version 3
2 Jan 2014 Submitted Manuscript version 3
Publishing
18 Jan 2014 Editorially accepted
21 Jan 2014 Article published 10.1186/1471-2407-14-35

You can find further information about peer review here.

Back to article page